Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Antiverse logo — Designing functional antibodies for the most challenging tar...

Antiverse

Designing functional antibodies for the most challenging targets.

Founded 2017 United Kingdom Cardiff, United Kingdom 33 employees Series A Total: $21.82M AI, Biotechnology +4

General Information

Company Name Antiverse
Founded Year 2017
Location United Kingdom Cardiff, United Kingdom
Employees 33
Industries AI, Biotechnology, Health Care +3
Funding Stage Series A
Business Model B2B, Platform, SaaS
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Antiverse. To contact Antiverse, visit antiverse.io.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Antiverse

Antiverse, founded in 2017, is a promising Welsh techbio company that specializes in the design of antibodies targeting difficult drug targets such as GPCRs and ion channels. The company’s mission is encapsulated in its slogan: "Designing functional antibodies for the most challenging targets."

With headquarters in Cardiff, UK, and offices in Boston, MA, Antiverse leverages cutting-edge machine learning and advanced cell line engineering to develop novel antibody therapeutics. The company's strategic position at the intersection of AI, Biotechnology, and Health Care makes it a significant contender in the Life Sciences and Pharmaceutical industries.

Recently, Antiverse closed a $9.30M Series A investment round on 01 March 2026, backed by an impressive roster of investors, including the Development Bank of Wales, i&I Bio, DOMiNO Ventures, Kadmos Capital Ltd, Soulmates Ventures, and Innovation Investment Capital.

Taxonomy: Antibody Design, Challenging Drug Targets, GPCR Therapeutics, Ion Channel Therapeutics, TechBio, Cell Line Engineering, De Novo Antibody Therapeutics, Drug Discovery, Structural Biology, Biotechnology Innovation, Therapeutic Antibodies, Accelerated Drug Development, Advanced Therapeutics

Services & Products

Antibody design for challenging targets
Pharmaceutical partnerships
In silico drug discovery
Machine learning model development

Target Customers

Pharmaceutical companies Biotech firms Healthcare researchers

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $9.30M 6
Development Bank of Wales i&I Bio DOMiNO Ventures
Development Bank of Wales, i&I Bio +4
01 Mar 2026
Seed €4.20M 6
AngelHub Future Planet Capital i&I Bio
AngelHub, Future Planet Capital +4
01 Oct 2024
Seed $3.00M 8
AngelHub Development Bank of Wales Innospark Ventures
AngelHub, Development Bank of Wales +6
01 Mar 2023
Seed £2.50M 6
AngelHub Development Bank of Wales Innospark Ventures
AngelHub, Development Bank of Wales +4
01 Oct 2022
Seed $2.00M 8
Development Bank of Wales UK Innovation & Science Seed Fund ACF Investors
Development Bank of Wales, UK Innovation & Science Seed Fund +6
01 Mar 2021
Grant £550.00K -
01 Jul 2020
Round Undisclosed 1
Future Planet Capital
Future Planet Capital
01 Jan 2020
Support Program Undisclosed 1
Tech Nation
01 Sep 2019
Grant £200.00K 1
Babraham Bioincubator
01 Jul 2018
Seed £70.00K -
01 Apr 2017

Latest News

View All
Antiverse secures $9.3M Series A for AI antibody platform — Tech
Antiverse secures $9.3M Series A for AI antibody platform
Tech Mar 03, 2026
Antiverse, DOMiNO Ventures'ın katıldığı turda 9,3 milyon dolar yatırım aldı — Webrazzi
Antiverse, DOMiNO Ventures'ın katıldığı turda 9,3 milyon dolar yatırım aldı
Webrazzi Mar 03, 2026
Cardiff-based Antiverse secures €4.2 million to advance generative AI antibody design — Eu-startups
Cardiff-based Antiverse secures €4.2 million to advance generative AI antibody design
Eu-startups Oct 16, 2024

Antiverse Alternatives & Competitors

View All Alternatives
Antiverse vs
MSM Protein Technologies, Inc.
MSM Protein Technologies, Inc.

Pioneering novel methods for precise targeting of challenging therapeutic proteins in drug discovery...

Seed
5 employees
Biotechnology, Health Care
Antiverse vs
Light Chain Bioscience | Novimmune SA
Light Chain Bioscience | Novimmune SA Switzerland

Light Chain Bioscience – A brand of Novimmune SA

Series C
76 employees
Biotechnology, Pharmaceutical
Antiverse vs
FogPharma
FogPharma United States

Until everything is druggable.

Series E
146 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Antiverse

Designing functional antibodies for the most challenging targets.
Antiverse was founded in 2017.
Antiverse is headquartered in Cardiff, United Kingdom.
Antiverse operates in AI, Biotechnology, Health Care, Life Sciences, Pharmaceutical and Machine Learning. Its work centres on Antibody Design, Challenging Drug Targets, GPCR Therapeutics and Ion Channel Therapeutics. Its customers include Pharmaceutical companies, Biotech firms and Healthcare researchers.
Antiverse has a B2B, Platform and SaaS business model. Its revenue comes from Licensing, Performance Based and Project Based.
Antiverse has approximately 33 employees.
Antiverse has completed 10 funding rounds, raising a total of $21.82M. The latest funding stage is Series A.
Antiverse offers: Antibody design for challenging targets, Pharmaceutical partnerships, In silico drug discovery, Machine learning model development.
Top alternatives and competitors to Antiverse include MSM Protein Technologies, Inc., Light Chain Bioscience | Novimmune SA, FogPharma, ProBio, Absci. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Antiverse and MSM Protein Technologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Antiverse, https://bouncewatch.com/company/antiverse, updated 23 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes